Gentherm Medical ($THRM) – a global market leader and developer of innovative thermal management technologies – previews the earnings report, which is expected to be released on October 29, 2020. At this point, noticeable improvements in the key figures have been shared in the company’s earnings outlook. If confirmed by the end of this week, the figures could cause the share to rise significantly. With a less favorable scenario, it can also have a negative effect on the volume.
What analysts share about this week
The stock has performed strongly in recent weeks leading up to the release, and momentum could carry on if analysts continue to raise earnings expectations. It is expected that Gentherm will deliver a year-over-year decline in earnings with lower revenues, once it reports the results for the quarter ended September 2020.
For the last quarter reported, it was expected that Gentherm would record a loss of $0.54 per share. In the end, it turned out to be a loss of $0.30 per share, which was a percentage improvement of +44.44%. In addition, the company has surpassed consensus WPA estimates four times in the past four quarters.
For the current quarter it is expected that Gentherm will earn $0.51 per share, which represents a percent change of -25% from its reported numbers in 2019. For the full year, the company is expected to earn $1.24 per share, representing a year-over-year change of -47.01%.Therefore a revenue is expected to reach $228.23 million, which equates to a 4.9% decline from the same quarter in 2019.
Over the past month it has risen one estimate higher with no negative revisions, increasing the consensus estimate by 5.98%. Shareholders believe in Gentherm for its solid estimate revisions, which is reflected in the share’s earnings of 8.3% over the past four weeks. The consensus estimate for the quarter has been revised 7.77% higher over the past month to its current level.
Analysts are highly optimistic about the earnings outlook boosting the stock price, which can be expressed even more if the predictions are found to be close to the figures in the report of this week. According to the analysts, an empirical study shows a strong correlation between trends in earnings estimate revisions and short-term stock price movements, which is a great sign for Gentherm.
Another motivation: ASTOPAD™
The FDA granted a 510(k) approval to Gentherm for the launched ASTOPAD™ Patient Warming System in the US. The ASTOPAD™ System can now be used in surgical procedures. It helps patients against hypothermia during the peri-operative process. Also referred to as a patient warming system, it is a proven device that has been in use outside of the US for over 30 years. Important are the patented heating blankets that allow the patient to be given a very accurate temperature.
ASTOPAD™ blankets are made from patented carbon fiber heating technology. The heating technology is mainly used for car seats, which has resulted in the installation of units in over 80 million vehicles. The unique design guarantees safety, durability and reliability.
Neither PSN nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision.